Ipamorelin vs Sermorelin

How they differ structurally

Sermorelin, CAS 86168-78-7, is a 29-amino-acid peptide corresponding to residues 1 through 29 of human growth-hormone-releasing hormone, which is why it’s also called GHRH 1-29. Native GHRH is longer, but the first 29 residues carry the full receptor-binding activity, and sermorelin is that fragment with a C-terminal amide and no other changes. It’s a natural-sequence peptide, which makes it more susceptible to enzymatic cleavage than a modified analogue like CJC-1295 no DAC, and that’s part of why it’s studied as the reference GHRH analogue. We stock it at 10mg, and the sermorelin learn page covers its history, including the fact that it was once an approved product in the US before being discontinued.

Ipamorelin, CAS 170851-70-4, is a pentapeptide, five residues, and shares no sequence with GHRH or with ghrelin. It was built from scratch in the 1990s as a growth hormone secretagogue and contains unnatural building blocks, including D-amino acids and a naphthylalanine residue, that give a chain this short enough stability and receptor affinity to be useful. Usually shortened to Ipa in the lab, it’s also stocked at 10mg, and the ipamorelin learn page goes through its design.

So one is a 29-residue natural fragment and the other is a five-residue synthetic with non-natural chemistry. Both are linear, neither is acylated or cyclised, and they’re structurally unrelated to each other in every respect except that both are peptides that act on the pituitary.

Receptor and mechanism differences

Sermorelin acts at the GHRH receptor, a G-protein-coupled receptor on the somatotroph cells of the anterior pituitary. Activation of that receptor raises cyclic AMP inside the somatotroph and drives both synthesis and release of growth hormone. It’s the primary physiological on-switch for growth hormone secretion, and because sermorelin is the native sequence, its receptor pharmacology is effectively that of the hormone itself. That makes it a clean positive control for GHRH receptor work.

Ipamorelin acts at the growth hormone secretagogue receptor, better known now as the ghrelin receptor since ghrelin was identified as its natural ligand. That receptor is also G-protein coupled but signals mainly through a different pathway, involving phospholipase C and intracellular calcium, and it’s expressed both on pituitary somatotrophs and in the hypothalamus. The original ipamorelin paper reported that it triggered growth hormone release in rat pituitary cells and in vivo without the accompanying rise in cortisol and prolactin seen with earlier secretagogues, which is the basis for calling it selective.

The two pathways aren’t independent. In published models, secretagogues appear to act partly by stimulating hypothalamic GHRH release and partly by direct action on the somatotroph, and the response to a secretagogue is blunted when GHRH signalling is blocked. That’s why the two classes are often combined in research designs and why, if you want to understand one receptor on its own, you need to think carefully about which compound isolates it. Sermorelin isolates the GHRH receptor cleanly. Ipamorelin isolates the ghrelin receptor at the level of binding, but its downstream effect in an intact animal involves both.

What the literature compares

Sermorelin has the older and, in some ways, the more complete record. GHRH(1-29) was characterised in the 1980s, and sermorelin itself went through a full clinical development program, was approved in the US as a diagnostic agent and for a paediatric indication, and was later withdrawn from the market for reasons that were commercial rather than safety-related as far as the public record shows. So there’s pituitary cell work, rodent work and human pharmacology all in the peer-reviewed literature. That regulatory history is a fact about the compound, and it tells you nothing about what a research vial is for.

Ipamorelin’s literature is smaller. The 1998 characterization paper from Novo Nordisk is the anchor, with its selectivity data in rat cells and in vivo, and there’s a modest set of later rodent studies, some on gastrointestinal motility, plus a short clinical program for post-operative ileus that didn’t progress. Independent confirmation of the selectivity profile from other groups is limited.

Direct comparisons of a GHRH analogue against a secretagogue in the same model exist, mostly from the period when the secretagogue class was being worked out, and they tend to report that the combination produces a larger growth hormone response than either alone. Studies that put sermorelin and ipamorelin specifically head to head, rather than other members of their classes, are few. If that’s your design, you’ll be adapting methods from the class literature rather than replicating a paired protocol.

Handling differences in the lab

At the bench, both are handled the same way. Each ships as a lyophilized powder in a sealed vial, and sealed vials belong at -20C, protected from light. When you reconstitute, use bacteriostatic water, let it run down the inside wall of the vial, and swirl gently until the solution is clear. No shaking. Keep the vial and everything that touches it sterile, label it with the compound, concentration and date, store the solution at 2-8C, use it within 28 days and avoid freeze-thaw.

The one real difference is how each holds up in solution. Sermorelin is a natural 29-residue sequence with no protective modifications, so once it’s in solution it’s the more fragile of the two: it’s a substrate for the same peptidases that clear native GHRH, and if your experimental medium contains serum or cell-derived enzymes you should expect it to degrade over the course of an assay. That’s a property you’ll want to account for in your timing rather than something you can prevent by storage. Ipamorelin, with its D-amino acids and non-natural residue, is far more resistant to enzymatic breakdown and is one of the more forgiving peptides we stock. Both dissolve readily, and ordinary polypropylene labware is fine for both, though the longer sermorelin chain has slightly more tendency to adsorb to surfaces at very low concentrations.

Which to order for which research question

If the question is about the GHRH receptor itself, cyclic AMP signalling in somatotrophs, or a reference GHRH response to compare a modified analogue against, sermorelin is the compound. It’s the native sequence, the literature treats it as the baseline, and it’s the natural comparator if you’re evaluating a stabilised analogue like CJC-1295 no DAC.

If the question is about the ghrelin receptor, the selectivity of secretagogues, or the hypothalamic contribution to growth hormone release, ipamorelin is the tool, and the 1998 paper is where to start reading. It’s also the better choice for any assay that runs long or involves enzyme-rich media, simply because it survives those conditions.

If the question is about how the two arms of the axis interact, order both and run each alone as a control alongside the combination. That’s the design most of the class literature used, and it’s the only way to attribute an effect to one receptor or the other. For any of these, each lot is tested for HPLC purity, mass spectrometry identity and bacterial endotoxin, by a named third-party lab, with the lot COA on the product page. Our certificate library is at /coas/. Both compounds come at >99% purity, vialed, finished, tested and shipped in the USA, and orders process within 1 business day.